生命科学资讯

Decoding Thermo Fisher Scientific Inc (TMO): A Strategic SWOT In - GuruFocus

Here’s What Analysts Think About Thermo Fisher Scientific (TMO) Post Earnings - Yahoo Finance

Assessing Illumina (ILMN) Valuation After Recent Share Price Momentum Shifts - simplywall.st

Spatial Biomarker Panels for Clinical Trials

Generate caps a strong month for biotech IPOs with $400M offering

Illumina Launches TruPath Genome, Unveils NovaSeq X Roadmap, and Drives Cancer Breakthroughs with Connected Multiomics - The Korea Herald

As CAR-T cell therapy gains ground on solid tumors, regulatory red tape hinders progress

'Like talking to a brick wall': Senate hearing takes aim at FDA's rare disease review process

Agilent Technologies (A) Margin Slippage Challenges Bullish Earnings Improvement Narrative - simplywall.st

Agilent Technologies (A) Margin Slippage Challenges Bullish Earnings Improvement Narrative - simplywall.st

The next generation is shaping the future of rare diseases - Illumina

The Analyst Verdict: Agilent Technologies In The Eyes Of 9 Experts - Benzinga

DOJ urges Supreme Court to undo revival of Hikma ‘skinny label’ case

Doug Ingram’s force of will meets its match as Sarepta CEO plans to depart

FDA probes internal Prasad complaints with outside help

Boehringer wins accelerated approval for first-line use of lung cancer drug

Sarepta CEO Doug Ingram to retire after a decade of Duchenne breakthroughs and controversies

Analysts see potential in MDMA drug after AtaiBeckley reports improvements in anxiety trial

Agilent Technologies (A) Sees Analyst Price Target Adjustment by UBS | A Stock News - GuruFocus

UBS Group Lowers Agilent Technologies (NYSE:A) Price Target to $165.00 - MarketBeat